Abstract
Panel next generation sequencing (NGS) of tumors has been rapidly adopted in molecular pathology. NGS is capable of detecting many types of genetic alterations within cancer genomes, however, assessment and reporting varies greatly among laboratories. Tumor cellularity influences mutational analysis and copy number estimation, particularly in unpaired (tumor-only) samples. Our institution utilizes a hybrid-capture targeted NGS panel in unpaired tumor specimens, with 20-90% tumor determined by histopathologic evaluation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
